Skip to main
KAPA

KAPA Stock Forecast & Price Target

KAPA Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kairos Pharma Ltd demonstrates a strong potential for growth, highlighted by a median progression-free survival of 13.7 months for the ENV-105 plus apalutamide regimen, indicating a competitive edge over traditional therapies. The company maintains a solid financial foundation with controlled cash burn, supported by recent capital raises and grants, which provide a sustainable runway for its ongoing clinical trials and development programs. Furthermore, the positive interim results from the Phase 2 trial of ENV-105 in advanced prostate cancer emphasize the effectiveness of its oncology pipeline and may attract strategic partnerships as the company progresses towards later-stage development.

Bears say

Kairos Pharma Ltd, a clinical-stage biopharmaceutical company, reported no product revenues for the quarter ended June 30, 2025, indicating a lack of commercial viability for its therapeutics at this stage. The company incurred a net loss of approximately $1.4 million for the three-month period and $2.7 million for the first half of 2025, which raises concerns about its financial sustainability. Despite some promising biological activity demonstrated in its treatments, the absence of revenue and ongoing losses highlight significant risks for investors looking at future growth potential.

KAPA has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kairos Pharma Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kairos Pharma Ltd (KAPA) Forecast

Analysts have given KAPA a Strong Buy based on their latest research and market trends.

According to 3 analysts, KAPA has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kairos Pharma Ltd (KAPA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.